Altamira Therapeutics Net Worth
Altamira Therapeutics Net Worth Breakdown | CYTO |
Altamira Therapeutics Net Worth Analysis
Altamira Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Altamira Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Altamira Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Altamira Therapeutics' net worth analysis. One common approach is to calculate Altamira Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Altamira Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Altamira Therapeutics' net worth. This approach calculates the present value of Altamira Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Altamira Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Altamira Therapeutics' net worth. This involves comparing Altamira Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Altamira Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Altamira Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Altamira Therapeutics' net worth research are outlined below:
| Altamira Therapeutics generated a negative expected return over the last 90 days | |
| Altamira Therapeutics has some characteristics of a very speculative penny stock | |
| Altamira Therapeutics has high historical volatility and very poor performance | |
| Altamira Therapeutics currently holds 99.66 K in liabilities with Debt to Equity (D/E) ratio of 0.05, which may suggest the company is not taking enough advantage from borrowing. Altamira Therapeutics has a current ratio of 0.75, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Altamira Therapeutics' use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (3.87 M) with loss before overhead, payroll, taxes, and interest of (2.18 M). | |
| Altamira Therapeutics currently holds about 984.19 K in cash with (11.51 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.29, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Altamira Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: ARMISTICE CAPITAL, LLC Acquires New Stake in Altamira Therapeutics Ltd |
Altamira Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Altamira Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Altamira Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 21st of May 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Know Altamira Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Altamira Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Altamira Therapeutics backward and forwards among themselves. Altamira Therapeutics' institutional investor refers to the entity that pools money to purchase Altamira Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Armistice Capital, Llc | 2024-09-30 | 101.4 K | Citadel Advisors Llc | 2024-09-30 | 14.8 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 1.9 K | Ubs Group Ag | 2024-06-30 | 1.7 K | Group One Trading, Lp | 2024-06-30 | 14.0 | Lri Investments, Llc | 2024-06-30 | 1.0 | Tower Research Capital Llc | 2024-06-30 | 0.0 |
Follow Altamira Therapeutics' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 1.52 M.Market Cap |
|
Project Altamira Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.91) | (2.01) | |
| Return On Capital Employed | (0.87) | (0.83) | |
| Return On Assets | (0.94) | (0.99) | |
| Return On Equity | (1.13) | (1.07) |
When accessing Altamira Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Altamira Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Altamira Therapeutics' profitability and make more informed investment decisions.
Evaluate Altamira Therapeutics' management efficiency
Altamira Therapeutics has return on total asset (ROA) of (0.5715) % which means that it has lost $0.5715 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.6878) %, meaning that it created substantial loss on money invested by shareholders. Altamira Therapeutics' management efficiency ratios could be used to measure how well Altamira Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 30th of November 2024, Return On Tangible Assets is likely to drop to -2.01. In addition to that, Return On Capital Employed is likely to grow to -0.83. At this time, Altamira Therapeutics' Debt To Assets are very stable compared to the past year. As of the 30th of November 2024, Asset Turnover is likely to grow to 0.05, while Total Assets are likely to drop about 7.3 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 13.15 | 12.50 | |
| Tangible Book Value Per Share | 5.22 | 4.96 | |
| Enterprise Value Over EBITDA | (0.68) | (0.71) | |
| Price Book Value Ratio | 0.22 | 0.23 | |
| Enterprise Value Multiple | (0.68) | (0.71) | |
| Price Fair Value | 0.22 | 0.23 | |
| Enterprise Value | 918.8 K | 872.9 K |
Understanding the operational decisions made by Altamira Therapeutics management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Enterprise Value Revenue 64.9314 | Revenue 120.3 K | Quarterly Revenue Growth (0.64) | Revenue Per Share 0.917 | Return On Equity (3.69) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Altamira Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Altamira Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Altamira Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Lokay Kevin G over two weeks ago Acquisition by Lokay Kevin G of 10000 shares of Altamira Therapeutics at 11.5 subject to Rule 16b-3 | ||
Carter Stephen over a month ago Disposition of 10000 shares by Carter Stephen of Altamira Therapeutics at 0.62 subject to Rule 16b-3 | ||
Mollica Joseph A over three months ago Acquisition by Mollica Joseph A of 198 shares of Altamira Therapeutics subject to Rule 16b-3 | ||
Schnittker Christopher P over six months ago Acquisition by Schnittker Christopher P of 18000 shares of Altamira Therapeutics at 5.15 subject to Rule 16b-3 | ||
Schnittker Christopher P over six months ago Acquisition by Schnittker Christopher P of 10000 shares of Altamira Therapeutics at 11.5 subject to Rule 16b-3 |
Altamira Therapeutics Earnings per Share Projection vs Actual
Altamira Therapeutics Corporate Management
| Covadonga Paeda | Chief Officer | Profile | |
| Covadonga Paneda | Chief Officer | Profile | |
| Jean Lechance | Unit Bus | Profile | |
| Samuel MD | Chief Officer | Profile | |
| Marcel CPA | Chief Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Altamira Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Altamira Stock, please use our How to Invest in Altamira Therapeutics guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Altamira Therapeutics. If investors know Altamira will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Altamira Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 1.82 | Revenue Per Share 0.917 | Quarterly Revenue Growth (0.64) | Return On Assets (0.57) | Return On Equity (3.69) |
The market value of Altamira Therapeutics is measured differently than its book value, which is the value of Altamira that is recorded on the company's balance sheet. Investors also form their own opinion of Altamira Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Altamira Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Altamira Therapeutics' market value can be influenced by many factors that don't directly affect Altamira Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Altamira Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Altamira Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Altamira Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.